Literature DB >> 17885826

Spatio-temporal localization of HIF-1alpha and COX-2 during irradiation-induced oral mucositis in a rat model system.

Chong-Jin Feng1, Jun-Bing Guo, Hong-Wei Jiang, Shuang-Xi Zhu, Chun-Yang Li, Bin Cheng, Yong Chen, Han-Yu Wang.   

Abstract

PURPOSE: Oral mucositis is a common side effect of radiotherapy for head and neck cancer. The purpose of this study was to examine the significance of and the relationship between hypoxia inducible factor-1alpha (HIF-1alpha) and cyclooxygenase-2 (COX-2) gene expression and the corresponding protein levels in irradiated rat mucosa.
MATERIAL AND METHODS: A Sprague-Dawley rat model of irradiation-induced oral mucositis was generated. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to evaluate the HIF-1alpha and COX-2 mRNA level in rat buccal mucosa exposed to a fractionated irradiation regime. The Streptavidin-Biotin-Complex method was applied to delineate the in situ localization, intensity, and distribution of both proteins. The right buccal mucosa was not irradiated and used as control tissue.
RESULTS: The RT-PCR analyses demonstrated that, upon irradiation, HIF-1alpha and COX-2 expression was significantly induced in the left buccal mucosa in contrast to control buccal mucosa. Based on immunohistochemical analyses, the HIF-1alpha and COX-2 level, in situ localization, and the type of cells exhibiting the highest HIF-1alpha and COX-2 amounts appear to correlate.
CONCLUSIONS: The expression and protein levels of HIF-1alpha and COX-2 are substantially enhanced in irradiated rat mucosa and correlate with each other and with the severity of irradiation-induced oral mucositis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17885826     DOI: 10.1080/09553000701616080

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  5 in total

1.  Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer.

Authors:  Rajesh V Lalla; Linda E Choquette; Kathleen F Curley; Robert J Dowsett; Richard S Feinn; Upendra P Hegde; Carol C Pilbeam; Andrew L Salner; Stephen T Sonis; Douglas E Peterson
Journal:  Oral Oncol       Date:  2014-08-21       Impact factor: 5.337

2.  Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats.

Authors:  Takako Nakashima; Naoya Uematsu; Kazushi Sakurai
Journal:  Support Care Cancer       Date:  2017-02-15       Impact factor: 3.603

3.  Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study.

Authors:  Rajesh V Lalla; Carol C Pilbeam; Stephen J Walsh; Stephen T Sonis; Dorothy M K Keefe; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2009-04-29       Impact factor: 3.603

4.  Text mining-based in silico drug discovery in oral mucositis caused by high-dose cancer therapy.

Authors:  Jon Kirk; Nirav Shah; Braxton Noll; Craig B Stevens; Marshall Lawler; Farah B Mougeot; Jean-Luc C Mougeot
Journal:  Support Care Cancer       Date:  2018-02-23       Impact factor: 3.603

5.  Radioprotective Effects of Dermatan Sulfate in a Preclinical Model of Oral Mucositis-Targeting Inflammation, Hypoxia and Junction Proteins without Stimulating Proliferation.

Authors:  Sylvia Gruber; Marlene Arnold; Nilsu Cini; Victoria Gernedl; Sabine Hetzendorfer; Lisa-Marie Kowald; Peter Kuess; Julia Mayer; Susanne Morava; Stephanie Pfaffinger; Andreas Rohorzka; Wolfgang Dörr
Journal:  Int J Mol Sci       Date:  2018-06-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.